Fever News and Research

RSS

VBI's flu vaccine offers protection against H1N1

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today reported that the company’s proprietary influenza vaccine triggered a robust immune response and provided protection against the H1N1 strain of influenza.

14 Sep 2009

Practical tips for parents on H1N1 and seasonal flu infections

With the early onset of flu season coinciding with the start of school this year, concern about the flu, and in particular the H1N1 strain of the flu, is growing among parents. Experts from The Children’s Hospital in Denver, Colo., can offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.

14 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

Survey reveals that hand-washing behaviors are poor despite H1N1 swine flu

With the White House estimating that 30 to 50 percent of Americans will contract H1N1 flu this season, you’d think more people would be focused on prevention.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

URV’s biosensor can detect typhoid causing bacteria instantly

A research group from the Rovira i Virgili University (URV) in Tarragona has developed a biosensor that can immediately detect very low levels of Salmonella typhi, the bacteria that causes typhoid fever. The technique uses carbon nanotubes and synthetic DNA fragments that activate an electric signal when they link up with the pathogen.

9 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).

5 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Damprid's recommendations for tackling seasonal allergy

For America’s 60 million seasonal allergy sufferers, fall can be one of the most difficult times of year as ragweed begins to release its pollen into the air and mold and fungus spores increase due to the decay of leaves and other plants. Each ragweed plant produces one billion pollen grains per average season. This generally continues until the first frost, usually in October.

3 Sep 2009

Gene-Eden antiviral supplement may offer protection against swine flu

Everyone is looking for ways to protect themselves against the swine flu virus. Let me tell you about my personal encounter with the virus. About three months ago, I read an article on Dr. Hanan Polansky's book, where he describes his discovery of the relationship between chronic viruses and chronic disease. After I read the article, I started taking Gene-Eden, a broad range antiviral supplement, to reduce the number of chronic viruses in my body.

3 Sep 2009

New York Times examines efforts to stop spread of dengue in Asia

"While emerging diseases like influenza A(H1N1), also known as swine flu, continue to dominate the headlines, experts say dengue is not only thriving in many endemic areas, it is also spreading to countries previously unaffected by the disease," New York Times writes.

3 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

CVS/pharmacy, the nation's leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced the availability of seasonal flu vaccinations and urged Americans to protect themselves early against the flu. CVS/pharmacy and MinuteClinic are divisions of CVS Caremark (NYSE: CVS), the largest provider of prescriptions in the country.

31 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

CDC report predicts that forty percent of Americans may be affected by the H1N1 flu

From summer camps to summer travel, the H1N1 influenza has taken a toll worldwide this season, and experts say the new flu strain is expected to be back in force this fall. Forty percent of Americans could end up being affected by the H1N1 flu, the CDC reported last month.

27 Aug 2009

Fever News and Research

VBI's flu vaccine offers protection against H1N1

Practical tips for parents on H1N1 and seasonal flu infections

NIH provides Inviragen second major grant to develop a dengue vaccine

Survey reveals that hand-washing behaviors are poor despite H1N1 swine flu

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

URV’s biosensor can detect typhoid causing bacteria instantly

Third human clinical trial of LigoCyte's norovirus vaccine started

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Damprid's recommendations for tackling seasonal allergy

Gene-Eden antiviral supplement may offer protection against swine flu

New York Times examines efforts to stop spread of dengue in Asia

FDA approves Meda's ASTEPRO Nasal Spray

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

CDC report predicts that forty percent of Americans may be affected by the H1N1 flu

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News